Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Details for Australian Patent Application No. 2004226805 (hide)

Owner Novartis AG

Inventors Shua-Haim, Joshua; Martenyi, Ferenc

Agent Davies Collison Cave

Pub. Number AU-B-2004226805

PCT Pub. Number WO2004/087166

Priority 60/459,338 01.04.03 US

Filing date 31 March 2004

Wipo publication date 14 October 2004

Acceptance publication date 6 March 2008

International Classifications

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 25/14 (2006.01) Drugs for disorders of the nervous system

Event Publications

6 October 2005 PCT application entered the National Phase

  PCT publication WO2004/087166 Priority application(s): WO2004/087166

6 March 2008 Application Accepted

  Published as AU-B-2004226805

3 July 2008 Standard Patent Sealed

28 October 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226807-Parenteral formulation of mycophenolic acid, a salt or prodrug thereof

2004226798-Swab for collecting biological specimens